RecruitingNCT06336382

Tau Biomarkers in Late-onset Psychosis (LOP)


Sponsor

Jeremy Koppel

Enrollment

16 participants

Start Date

Feb 16, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.


Eligibility

Min Age: 65 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether brain protein changes (tau biomarkers) associated with Alzheimer's disease are also present in older adults who develop psychosis for the first time late in life — a condition called late-onset psychosis. Understanding this link could improve diagnosis and care. **You may be eligible if...** - You are between 65 and 85 years old - You have been diagnosed with late-onset schizophrenia-like psychosis or delusional disorder - A caregiver is available to provide additional information about your history - Your cognitive function is largely intact (MMSE score of 24 or higher, CDR of 0 or 0.5) - Your memory tests are within the normal range (ruling out MCI) **You may NOT be eligible if...** - You have significant hearing difficulties - You have a dementia diagnosis or score below the normal range on cognitive tests - You are unable to participate in neuropsychological assessments - You have other neurological conditions that better explain your symptoms Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTTau PET imaging scan

Subjects will be scanned with novel tau PET tracer \[18F\] PI-2620 to determine whether neurofibrillary tangle pathology is present.


Locations(1)

The Feinstein Institutes for Medical Research

Manhasset, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06336382